Smallpox is a CDC Category A bioterrorism agent caused by variola virus (an orthopoxvirus), eradicated globally since 1980 but remaining a critical biothreat. Any single suspected case constitutes an international public health emergency requiring immediate notification of local/state health departments and the CDC. [1-3] The fatality rate of variola major is approximately 25–30% in unvaccinated individuals. [1][3]
The following figure from Breman & Henderson (NEJM, 2002) illustrates the clinical progression, pathogenesis, and immune response timeline of smallpox:
1. History
- Exposure context: Any case in the modern era implies deliberate release (bioterrorism) or laboratory accident — ask about travel, occupational exposure to research labs, contact with known cases, or suspicious events [1][4]
- Incubation period: 7–17 days (mean 10–14 days); ask about timeline from potential exposure [2][5]
- Prodrome (1–4 days before rash): Abrupt onset of high fever (38.9–40.6°C), severe prostration, headache, backache (up to 90% of patients), chills, vomiting, severe abdominal pain [2][5-6]
- Rash progression: Enanthem (oral mucosa) → exanthem starting on face → spreading to extremities and trunk within 24–48 hours; macules → papules (day 2) → vesicles (days 4–5) → pustules (day 7) → crusting (2–3 weeks) [5-6]
- Key distinguishing features: Lesions all in the same stage of development on any given body part; centrifugal distribution (face/extremities > trunk); lesions on palms and soles; deep-seated, firm, round, well-circumscribed [5]
- Important negatives: Absence of lymphadenopathy (distinguishes from mpox); no crops of lesions at different stages (distinguishes from varicella) [6-7]
2. Alarm Features
- Hemorrhagic smallpox: Dusky erythema, petechiae, frank hemorrhages into skin/mucous membranes; death by day 5–6 of rash; ~98% fatality; more common in pregnant women [1][8]
- Flat (malignant) smallpox: Soft, flat, confluent lesions that do not project above skin; 94–97% case fatality rate [2][8]
- Confluent ordinary smallpox: Mortality ~50–60% vs. 10% for discrete ordinary type [5][8]
- Encephalitis: Occurs in <1% of cases; decreased consciousness, seizures [2][6]
- Respiratory decompensation: Bronchopneumonia, secondary bacterial infection — more likely with severe/confluent disease [2]
- Delirium/encephalopathy: ~15% of patients during febrile stage; febrile seizures in ~7% of children <5 years [6]
3. Medications
Antiviral Treatment:
- Tecovirimat (TPOXX): FDA-approved for treatment of smallpox in adults and pediatric patients ≥3 kg [9-10]
- Oral dosing (14-day course): 13–<25 kg: 200 mg q12h; 25–<40 kg: 400 mg q12h; 40–<120 kg: 600 mg q12h; ≥120 kg: 600 mg q8h [10]
- IV formulation available for patients unable to take oral [10-11]
- Mechanism: Inhibits VP37 envelope wrapping protein, blocking extracellular viral dissemination [12-13]
- Efficacy not proven in human smallpox (approved under FDA Animal Rule); may be reduced in immunocompromised patients [4][10]
- CYP450 interactions — check drug-drug interactions, especially with antiretrovirals [14]
- Cidofovir / Brincidofovir: Alternative antivirals with in vitro activity against variola; potential role if tecovirimat resistance emerges [15-16]
- Vaccinia Immune Globulin Intravenous (VIGIV): Available for passive immunization; indicated for vaccine complications (eczema vaccinatum, progressive vaccinia) [3][15]
Contraindicated/Cautions:
- No role for standard antivirals (acyclovir, valacyclovir) — these target herpesvirus thymidine kinase, not orthopoxviruses
- Tecovirimat resistance mutations have been identified, particularly in immunocompromised patients [12]
4. Diet
- No specific dietary triggers or restrictions
- Hydration is critical — patients with extensive oropharyngeal enanthem may have difficulty swallowing, leading to dehydration [2][8]
- Nutritional support and caloric supplementation for severely ill, bedridden patients
- Soft/liquid diet may be necessary during the pustular phase due to oral mucosal involvement
5. Review of Systems
- Constitutional: Fever, rigors, prostration, malaise (universal in prodrome) [2][5]
- Dermatologic: Rash character, distribution, stage of evolution, palms/soles involvement
- HEENT: Oral enanthem, dysphagia, eye involvement (keratitis, conjunctival lesions) [2]
- Respiratory: Cough (not prominent but assess for pneumonia), dyspnea [2]
- Neurologic: Headache, backache, delirium, seizures, altered consciousness [6]
- GI: Abdominal pain, vomiting (prodromal), diarrhea
- MSK: Arthritis/joint pain (especially in children — osteomyelitis variolosa in 2–5%) [2][6]
- Lymphatic: Absence of lymphadenopathy (helps distinguish from mpox) [5-6]
6. Collateral History and Family History
- Contact tracing is paramount: Identify all face-to-face and household contacts for immediate vaccination and surveillance [1-2]
- Vaccination history: Prior smallpox vaccination (pre-1980s) may confer partial protection — modified/milder disease in previously vaccinated individuals [2][5]
- Occupational history: Laboratory workers handling orthopoxviruses, military personnel
- Travel history: Relevant only in context of bioterrorism investigation
- Pregnancy status: Pregnant women are at increased risk for hemorrhagic smallpox and higher mortality [1][8]
- Immunocompromised status: HIV, transplant recipients, chemotherapy — increased risk of severe disease [10]
7. Risk Factors
- Unvaccinated status: Global vaccination ceased in the 1980s; the vast majority of the current population is susceptible [4][15]
- Pregnancy: Disproportionately high risk for hemorrhagic smallpox; CFR 28% vs. 8% in non-pregnant women in historical data [8]
- Immunosuppression: Reduced efficacy of both vaccination and antiviral therapy [10]
- Young children and elderly: Higher morbidity and mortality
- Close/household contact with an infected individual: Primary mode of person-to-person spread via respiratory droplets and direct contact [1]
- Healthcare workers without vaccination: High-risk occupational exposure [1][3]
8. Differential Diagnosis
The following figure compares the distribution of skin lesions in varicella, smallpox, and mpox:
9. Past Medical History
- Prior smallpox vaccination: Determines risk of modified vs. ordinary disease; vaccination scars (typically deltoid) may be present in individuals born before ~1972 (US) [2][5]
- Immunodeficiency: HIV/AIDS, organ transplant, active chemotherapy — impacts disease severity and treatment response [10]
- Eczema/atopic dermatitis: Historically associated with eczema vaccinatum from vaccination; relevant if vaccination is being considered [3]
- Cardiac history: ACAM2000 vaccine carries risk of myopericarditis (~5.7 per 1000 vaccinees) [3]
- Pregnancy: Contraindication to live vaccines (ACAM2000); JYNNEOS (MVA-based, non-replicating) may be considered [3][15]
10. Physical Exam
- Vital signs: High fever (38.9–40.6°C) during prodrome; tachycardia; hypotension in severe/hemorrhagic cases [2][5]
- Skin: Deep-seated, firm, round, well-circumscribed vesicles/pustules; all lesions in same stage on any body region; centrifugal distribution; check palms and soles [5]
- Oral cavity: Enanthem on tongue, buccal mucosa, oropharynx — appears ~24 hours before exanthem [2][5]
- Eyes: Assess for keratitis, conjunctival lesions [2]
- Lymph nodes: Absence of significant lymphadenopathy (present = think mpox) [5-6]
- Respiratory: Auscultate for pneumonia signs
- Neurologic: Mental status, signs of encephalitis or meningismus [6]
- Hemorrhagic variant: Petechiae, purpura, ecchymoses, mucosal bleeding [1][8]
11. Lab Studies
- Definitive diagnosis requires BSL-4 laboratory confirmation — do NOT send to routine hospital labs [1-2][5]
- Specimen collection: Vesicular/pustular fluid (open with blunt scalpel, swab), scab scrapings, blood, tonsillar swabs; collector should ideally be recently vaccinated and wear full PPE [1-2]
- PCR: Real-time PCR for orthopoxvirus DNA and variola-specific sequences — most rapid and specific [2][5]
- Electron microscopy: Identifies characteristic brick-shaped orthopoxvirus virions (cannot distinguish variola from other orthopoxviruses) [1-2]
- Viral culture: Growth on cell lines or chorioallantoic membrane — confirmatory but slower [1-2]
- Serology: Does not differentiate among orthopoxvirus species; paired sera needed; IgM may enhance early diagnosis [2][5]
- Routine labs: CBC, CMP, coagulation studies for supportive care; blood cultures if secondary bacterial infection suspected
- Rule-out testing: VZV PCR, HSV PCR to exclude varicella and herpes in moderate-risk cases before pursuing variola testing [5]
12. Imaging
- Chest X-ray: Indicated if respiratory symptoms develop; assess for bronchopneumonia (more common in severe/confluent disease) [2]
- No pathognomonic imaging findings for smallpox itself
- Imaging is primarily supportive — to evaluate complications (pneumonia, ARDS)
- Routine imaging is unnecessary in uncomplicated cases
13. Special Tests
CDC Smallpox Evaluation Algorithm (Major and Minor Criteria): [5]
Major criteria (any present raises suspicion):
- Febrile prodrome (≥38.3°C) with prostration, headache, backache, chills, vomiting, or severe abdominal pain, occurring 1–4 days before rash
- Classic smallpox lesions: deep-seated, firm, round, well-circumscribed vesicles/pustules; may become umbilicated or confluent
- Lesions in same stage of development on any one body part
Minor criteria include: centrifugal distribution, first lesions on face/oral mucosa, patient appears toxic/moribund, slow evolution of lesions (each stage lasting 1–2 days), and lesions on palms/soles.
- Point-of-care: ABICAP immunofiltration assay can produce results in ~45 minutes [16]
- Skin biopsy: Histopathology shows intraepidermal multilocular vesicles with ballooning degeneration and cell necrosis [2]
- Tzanck smear: Useful to rule out herpes (multinucleated giant cells) but does not confirm smallpox
14. ECG
- Not a primary diagnostic tool for smallpox
- ECG indicated if:
- Hemodynamic instability or shock (hemorrhagic smallpox) — assess for myocarditis or ischemia
- Post-vaccination with ACAM2000 — monitor for myopericarditis (ST changes, PR depression, new arrhythmias) [3]
- Sepsis from secondary bacterial infection
15. Assessment
Clinical Classification (WHO): [2][5-6][8]
- Ordinary smallpox (~90% of cases): Classic pustular rash; CFR ~30% unvaccinated (10% discrete, 50–60% confluent)
- Modified smallpox: Milder, accelerated course in previously vaccinated; rarely fatal
- Variola sine eruptione: Fever without rash; occurs in vaccinated contacts or infants with maternal antibodies; does not transmit
- Flat (malignant) smallpox (~7%): Soft, flat, confluent lesions; CFR 94–97%
- Hemorrhagic smallpox (~2–3%): Petechiae, hemorrhages, DIC-like picture; CFR ~98%; death by day 5–6; not reduced by prior vaccination
Complications: Pockmark scarring (65–80% of survivors), blindness from keratitis (~1%), arthritis/osteomyelitis (2–5% of children), encephalitis (<1%), bronchopneumonia, secondary bacterial sepsis [2][6]
16. Treatment Plan
Immediate Actions:
- Isolate the patient immediately — airborne + contact precautions; negative pressure room if available [1-3]
- Notify public health authorities — state health department → CDC (770-488-7100, 24/7) → WHO [2]
- Supportive care is the mainstay: IV fluids, antipyretics, pain management, nutritional support [1][16]
Antiviral Therapy:
- Tecovirimat (TPOXX) — initiate as soon as possible; 14-day course; weight-based dosing as above [10]
- Consider cidofovir or brincidofovir if tecovirimat unavailable or resistance suspected [15]
- VIGIV for vaccine-related complications [3][15]
Vaccination of Contacts:
- Ring vaccination strategy: Vaccinate all household and face-to-face contacts within 2–3 days of exposure (up to 4 days may still attenuate disease) [1-3]
- ACAM2000: Live vaccinia vaccine; single percutaneous dose; contraindicated in severe immunosuppression, eczema, pregnancy [3]
- JYNNEOS (MVA-BN): Non-replicating; safer for immunocompromised and pregnant patients; stockpiled for emergency use [14-15]
Secondary Infection Management:
17. Disposition
- A single case of smallpox is a global public health emergency [2][4]
- Isolation is mandatory for all confirmed or suspected cases [1][3]
- Home isolation preferred when feasible to reduce nosocomial spread; hospital admission reserved for severe disease (hemorrhagic, flat, respiratory compromise, encephalitis) [1]
- Admission criteria: Hemodynamic instability, hemorrhagic or flat-type disease, respiratory failure, encephalitis, inability to maintain hydration, pregnancy with severe disease
- All healthcare workers must use airborne + contact precautions regardless of vaccination status [2-3]
- Specialist consultation: Infectious disease, public health/epidemiology, dermatology; critical care for severe cases
- Law enforcement/bioterrorism response should be activated concurrently [1]
18. Follow Up / Return Precautions
- Infectiousness persists from rash onset until all scabs have separated (typically 3–4 weeks) [1][3]
- Contacts under surveillance: Monitor for fever and rash for 17 days after last exposure [1]
- Survivors: Expect pockmark scarring in 65–80%; ophthalmologic follow-up for keratitis/blindness risk; orthopedic follow-up for children with arthritis [2]
- Lifelong immunity is conferred after natural infection [2]
- Return precautions for contacts: Seek immediate medical attention for any fever ≥38.3°C, rash, or constitutional symptoms during the surveillance period
- Psychological support: Significant morbidity from disfigurement; PTSD considerations in bioterrorism context
References
1. Smallpox as a Biological Weapon: Medical and Public Health Management. — Henderson DA, Inglesby TV, Bartlett JG, et al. The Journal of the American Medical Association. 1999.
2. Smallpox as a Biological Weapon: Medical and Public Health Management. — Henderson DA, Inglesby TV, Bartlett JG, et al. The Journal of the American Medical Association. 1999.
3. Smallpox as a Biological Weapon: Medical and Public Health Management. — Henderson DA, Inglesby TV, Bartlett JG, et al. The Journal of the American Medical Association. 1999.
4. Diagnosis and Management of Smallpox. — Breman JG, Henderson DA. The New England Journal of Medicine. 2002.
5. Diagnosis and Management of Smallpox. — Breman JG, Henderson DA. The New England Journal of Medicine. 2002.
6. Clinical Management of Potential Bioterrorism-Related Conditions. — Adalja AA, Toner E, Inglesby TV. The New England Journal of Medicine. 2015.
7. Clinical Management of Potential Bioterrorism-Related Conditions. — Adalja AA, Toner E, Inglesby TV. The New England Journal of Medicine. 2015.
8. Oral Tecovirimat for the Treatment of Smallpox. — Grosenbach DW, Honeychurch K, Rose EA, et al. The New England Journal of Medicine. 2018.
9. Oral Tecovirimat for the Treatment of Smallpox. — Grosenbach DW, Honeychurch K, Rose EA, et al. The New England Journal of Medicine. 2018.
10. Smallpox. — Moore ZS, Seward JF, Lane JM. Lancet. 2006.
11. Smallpox. — Moore ZS, Seward JF, Lane JM. Lancet. 2006.
12. Neurologic Complications of Smallpox and Monkeypox: A Review. — Billioux BJ, Mbaya OT, Sejvar J, Nath A. JAMA Neurology. 2022.
13. Neurologic Complications of Smallpox and Monkeypox: A Review. — Billioux BJ, Mbaya OT, Sejvar J, Nath A. JAMA Neurology. 2022.
14. Monkeypox: An international epidemic. — Focosi D, Novazzi F, Baj A, Maggi F. Reviews in Medical Virology. 2022.
15. Monkeypox: An international epidemic. — Focosi D, Novazzi F, Baj A, Maggi F. Reviews in Medical Virology. 2022.
16. Pandemic potential of poxviruses: From an ancient killer causing smallpox to the surge of monkeypox. — Brüssow H. Microbial Biotechnology. 2023.
17. Pandemic potential of poxviruses: From an ancient killer causing smallpox to the surge of monkeypox. — Brüssow H. Microbial Biotechnology. 2023.
18. FDA Orange Book. — FDA Orange Book. 2026.
19. FDA Orange Book. — FDA Orange Book. 2026.
20. FDA Drug Label. — Updated date: 2025-12-31. Food and Drug Administration.
21. FDA Drug Label. — Updated date: 2025-12-31. Food and Drug Administration.
22. Overview of the Regulatory Approval of Tecovirimat Intravenous Formulation for Treatment of Smallpox: Potential Impact on Smallpox Outbreak Response Capabilities, and Future Tecovirimat Development Potential. — Russo AT, Grosenbach DW, Honeychurch KM, Long PG, Hruby DE. Expert Review of Anti-Infective Therapy. 2023.
23. Overview of the Regulatory Approval of Tecovirimat Intravenous Formulation for Treatment of Smallpox: Potential Impact on Smallpox Outbreak Response Capabilities, and Future Tecovirimat Development Potential. — Russo AT, Grosenbach DW, Honeychurch KM, Long PG, Hruby DE. Expert Review of Anti-Infective Therapy. 2023.
24. Tecovirimat: A Journey From Discovery to Mechanistic Insights in Poxvirus Inhibition. — Li X, Pan Z, Zhang L. PLoS Pathogens. 2025.
25. Tecovirimat: A Journey From Discovery to Mechanistic Insights in Poxvirus Inhibition. — Li X, Pan Z, Zhang L. PLoS Pathogens. 2025.
26. An Update on Mpox: Focussing on Current and Emerging Antiviral Strategies. — Hou Y, Su Y, Li J, Ding J. Reviews in Medical Virology. 2026.
27. An Update on Mpox: Focussing on Current and Emerging Antiviral Strategies. — Hou Y, Su Y, Li J, Ding J. Reviews in Medical Virology. 2026.
28. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. — Bill G. Kapogiannis, Franklin Yates, Wei Li, et al Office of AIDS Research Advisory Council (2025). 2025.
29. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. — Bill G. Kapogiannis, Franklin Yates, Wei Li, et al Office of AIDS Research Advisory Council (2025). 2025.
30. Treatment and Vaccination for Smallpox and Monkeypox. — Saalbach KP. Advances in Experimental Medicine and Biology. 2024.
31. Treatment and Vaccination for Smallpox and Monkeypox. — Saalbach KP. Advances in Experimental Medicine and Biology. 2024.
32. Confronting the Threat of Bioterrorism: Realities, Challenges, and Defensive Strategies. — Green MS, LeDuc J, Cohen D, Franz DR. The Lancet. Infectious Diseases. 2019.
33. Confronting the Threat of Bioterrorism: Realities, Challenges, and Defensive Strategies. — Green MS, LeDuc J, Cohen D, Franz DR. The Lancet. Infectious Diseases. 2019.
34. Mpox—A Rapidly Evolving Disease. — Cowen EW, Tkaczyk ER, Norton SA, Leslie KS. JAMA Dermatology. 2023.
35. Mpox—A Rapidly Evolving Disease. — Cowen EW, Tkaczyk ER, Norton SA, Leslie KS. JAMA Dermatology. 2023.